|
10002
|
CoronaVac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sinovac Biotech Ltd.
|
2021
|
China
|
18 - 59 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
Antigenic strain of H1N1, H3N2, BV and BY
|
NA
|
NA
|
NA
|
NA
|
PiCoVacc, Inactivated SARS-CoV-2 vaccine (Vero cell)
|
NA
|
NCT04801888
|
https://clinicaltrials.gov/show/NCT04801888
|
https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/4_sage29apr2021_sinovac.pdf
|
|
10003
|
Inactivated SARS-CoV-2 vaccine (Vero cell)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Hubei Provincial Center for Disease Control and Prevention
|
2020
|
China
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
http://www.chictr.org.cn/showproj.aspx?proj=126385
|
NA
|
|
10004
|
Inactivated SARS-CoV-2 vaccine (Vero cell)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Shanghai Municipal Center for Disease Control and Prevention
|
2021
|
China
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
http://www.chictr.org.cn/showproj.aspx?proj=126277
|
NA
|
|
10005
|
KconecaVac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Shenzhen Kangtai Biological Products Co. Ltd
|
2021
|
China
|
18 years and above
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
China FDA
|
NA
|
NA
|
NA
|
NA
|
NCT04852705
|
https://clinicaltrials.gov/show/NCT04852705
|
https://www.reuters.com/article/us-health-coronavirus-vaccine-kangtai/kangtai-biologicals-covid-19-vaccine-gets-emergency-use-approval-in-china-idUSKBN2CV1F6
|
|
10006
|
Inactivated SARS-CoV-2 vaccine (Vero cell)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Shanghai Oriental Hospital
|
2021
|
China
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
http://www.chictr.org.cn/showproj.aspx?proj=122756
|
NA
|
|
10012
|
SARS-CoV-2 Vaccine (VeroCell)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sinopharm, Beijing Institute of Biological Products
|
2020
|
China
|
NA
|
2 doses 21 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
WHO
|
NA
|
NA
|
NA
|
33816047
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
https://cdn.who.int/media/docs/default-source/immunization/covid-19/16-june-22080-sinopharm-vaccine-explainer-update.pdf?sfvrsn=ad833095_1&download=true
|
|
10031
|
Covaxin
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Bharat Biotech International Limited
|
2021
|
India
|
18 years and above
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
DCGI, WHO
|
Indian Council of Medical Research, Iqvia Pty Ltd
|
NA
|
NA
|
NA
|
NCT04641481
|
https://clinicaltrials.gov/ct2/show/NCT04641481
|
https://www.clinicaltrialsarena.com/projects/covaxin-bbv152-for-the-treatment-of-covid-19/
|
|
10041
|
COVILO (BBIBP-CorV)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
China National Biotec Group Company Limited
|
2021
|
China
|
3 years and above
|
2 doses 21 days apart
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Inactivated SARS-CoV-2 virus
|
Inactivated SARS-CoV-2 vaccine (Vero cell) is prepared by inoculating African green monkey kidney cells (Vero cell) with the SARS-CoV-2 HB02 strain
|
WHO, Caribbean Regulatory System Emergency Use Recommendation
|
Beijing Institute of Biotechnology
|
China, Bahrain, Egypt, Jordan, UAE, Hungary, Pakistan
|
NA
|
33402220
|
NCT04863638
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/
|
https://www.carpha.org/Portals/0/Documents/COVID-19%20Vaccine%20Updates/CARPHA%20COVID-19%20Vaccine%20Update%20047%20December%206%202021.pdf
|
|
10042
|
PiCoVacc
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sinovac Biotech Ltd.
|
2021
|
Brazil
|
18 - 59 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
Inactivated SARS-CoV-2 virus
|
NA
|
WHO, Caribbean Regulatory System Emergency Use Recommendation, Africa Regulatory Taskforce Endorsed
|
NA
|
NA
|
CoronaVac
|
33402220
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/
|
https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations
|
|
10049
|
CoronaVac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sinovac Biotech Ltd.
|
NA
|
China
|
18 years and above
|
NA
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Inactivated SARS-CoV-2 virus
|
Vero cells
|
NMPA, WHO
|
NA
|
NA
|
Inactivated SARS-CoV-2 Vaccine (Vero Cell) (lnCoV),CoronaVac
|
NA
|
NA
|
https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf
|
https://clinicaltrials.gov/ct2/show/NCT05107557
|
|
10053
|
Covaxin
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Bharat Biotech International Limited
|
NA
|
India
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
Produced in vero cells
|
DCGI
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf
|
https://www.precisionvaccinations.com/vaccines/covaxin-covid-19-vaccine
|
|
10059
|
VLA2001
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Valneva
|
2021
|
Austria
|
18 years and above
|
2 doses 28 days apart
|
Intramuscular
|
CpG 1018, aluminium hydroxide
|
NA
|
NA
|
EMA
|
NA
|
NA
|
NA
|
NA
|
NCT04864561
|
https://clinicaltrials.gov/show/NCT04864561
|
https://valneva.com/press-release/valneva-receives-marketing-authorization-in-europe-for-inactivated-whole-virus-covid-19-vaccine-vla2001/#:~:text=VLA2001%20is%20the%20only%20whole,to%2050%20years%20of%20age.
|
|
10063
|
COVIran Barekat
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Shifa Pharmed Industrial Co.
|
2021
|
Iran
|
18 - 75 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
Iran FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://en.irct.ir/trial/54881
|
https://www.rferl.org/a/iran-domestic-covid-vaccine-coviran-barekat/31307467.html
|
|
10066
|
FAKHRAVAC
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Erciyes University, Organization of Defensive Innovation and Research
|
2021
|
Iran
|
18 - 70 years
|
NA
|
Intramuscular
|
NA
|
SARS-CoV-2
|
NA
|
Iran FDA
|
Organization of Defensive Innovation and Research
|
NA
|
MIVAC, TURKOVAC
|
NA
|
NA
|
https://en.irct.ir/trial/56027
|
https://www.tehrantimes.com/news/466570/Two-homegrown-vaccines-receive-emergency-use-license
|
|
10067
|
KCONVAC
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Shenzhen Kangtai Biological Products Co. Ltd
|
2021
|
China
|
18 years and above
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
China FDA
|
Beijing Minhai Biotechnology Co.
|
China, Indonesia
|
NA
|
NA
|
NCT05204589
|
https://clinicaltrials.gov/ct2/show/NCT05204589
|
https://www.reuters.com/article/us-health-coronavirus-vaccine-kangtai/kangtai-biologicals-covid-19-vaccine-gets-emergency-use-approval-in-china-idUSKBN2CV1F6
|
|
10068
|
Afluria Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
2007
|
Australia
|
6 months - 35 months
|
NA
|
Intramuscular
|
NA
|
NA
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10069
|
Afluria Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
2007
|
Australia
|
3 years and above
|
NA
|
Intramuscular
|
NA
|
NA
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10070
|
Afluria Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
6 months - 64 years
|
NA
|
Intramuscular
|
Thimerosal (24.5) Mercury
|
NA
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10071
|
Fluarix Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
NA
|
6 months and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10072
|
FluLaval Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
NA
|
7 months and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10073
|
Fluzone Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
8 months and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10074
|
Fluzone Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
9 months and above
|
NA
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10075
|
Fluzone Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
10 months and above
|
NA
|
Intramuscular
|
Thimerosal (24.5) Mercury
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10076
|
Flucelvax Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
4 years and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Cell culture based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10077
|
Flucelvax Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
4 years and above
|
NA
|
Intramuscular
|
Thimerosal (24.5) Mercury
|
Hemagglutinin
|
Cell culture based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10078
|
Fluzone High-Dose Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
65 years and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10079
|
Fluad Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
65 years and above
|
Single dose
|
Intramuscular
|
MF59
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10080
|
Fluad Trivalent IIV (IIV3)
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
65 years and above
|
Single dose
|
Intramuscular
|
MF59
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10083
|
IL-YANG Quadrivalent Seasonal Influenza Vaccine
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Ilyang pharmaceutical Co. Ltd.
|
2020
|
South Korea
|
3 - 18 years
|
Single dose
|
Intramuscular
|
NA
|
Inactivated Influenza virus
|
NA
|
MFDS
|
NA
|
NA
|
NA
|
NA
|
NCT03445468
|
https://clinicaltrials.gov/ct2/show/NCT03445468?recrs=ade&cond=Influenza%2C+Human&phase=23&draw=2&rank=4
|
https://www.clincosm.com/trial/influenza-il-yang-quadrivalent-vaccine-flu-prefilled-syringe
|
|
10092
|
HAVRIX
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
Belgium
|
NA
|
P: 720 EU; Adults: 1440 EU; 2 doses 0, 6–12
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
HM-175
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert---HAVRIX.pdf
|
|
10093
|
VAQTA
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Merck & Co. Inc.
|
NA
|
USA
|
NA
|
P: 25 U; Adults: 50 U; 2 doses 0, 6–18
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
CR-326
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/vaqta
|
|
10094
|
AVAXIM
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
Lyon, France
|
NA
|
P: 80 U; Adults: 160 U
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
GBM
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.fda.moph.go.th/sites/drug/Shared%20Documents/Vaccine/U1DR1C1062460010911C-SPC.pdf
|
|
10095
|
Healive
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sinovac Biotech Ltd.
|
NA
|
China
|
NA
|
P: 250 U; Adults: 500 U
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
TZ-84
|
NA
|
China FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
http://www.sinovac.com/news/shownews.php?id=764&lang=en
|
|
10096
|
Weisairuiji Biovac-A Mevac-A
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Institute of Medical Biology, Chinese Academy of Medical Sciences
|
NA
|
China
|
NA
|
P: 320 EU; Adults: 640 EU
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Lv-8
|
NA
|
China FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482852/
|
|
10097
|
Veraxim
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Shanghai Wilson Bioengineering
|
NA
|
China
|
NA
|
P: 800 EU; Adults: 1600 EU
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
YN-5
|
NA
|
Government of China
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
|
10098
|
HAVRIX
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
Belgium
|
12 months and above
|
Single dose for adult and 2 doses 6 to 12 months apart for infants
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hav/havfaq.htm#vaccine
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/havrix
|
|
10099
|
VAQTA
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Merck & Co. Inc.
|
NA
|
USA
|
12 months and above
|
2 doses 6 to 18 months apart
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hav/havfaq.htm#vaccine
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/vaqta
|
|
10100
|
TWINRIX
|
Hepatitis A, Hepatitis B
|
Hepatitic
|
Hepatitis A, Hepatitis B virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
Rixensart, Belgium
|
18 years and above
|
3 doses at regimen of 0, 1, and 6 months
|
Intramuscular
|
Aluminum
|
Strain HM175, HBsAg
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hav/havfaq.htm#vaccine
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/twinrix
|
|
10109
|
AMBIRIX
|
Hepatitis A, Hepatitis B
|
Hepatitic
|
Hepatitis A, Hepatitis B virus
|
double stranded DNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
2002
|
Belgium
|
1 - 15 years
|
2 doses 6 to 12 months apart
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Inactivated hepatitis A virus and surface antigen of hepatitis B virus
|
Produced on human diploid (MRC-5) cells
|
EMA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf
|
https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf
|
|
10110
|
AMBIRIX
|
Hepatitis A, Hepatitis B
|
Hepatitic
|
Hepatitis A, Hepatitis B virus
|
double stranded DNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
2002
|
Belgium
|
2 - 15 years
|
2 doses 6 to 12 months apart
|
Intramuscular
|
Aluminum (aluminum phosphate)
|
Inactivated hepatitis A virus and surface antigen of hepatitis B virus
|
Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology
|
EMA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf
|
https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf
|
|
10112
|
Imovax Rabies(Pre exposure)
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
2005
|
France
|
All age group
|
3 doses on day 0, 7 and 21
|
Intramuscular
|
NA
|
WISTAR Rabies PM/WI38-1503-3M strain
|
Human diploid cell vaccine
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/imovax
|
|
10113
|
Imovax Rabies(Post exposure)
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
2005
|
France
|
All age group
|
5 doses on day 0, 3, 7, 14 and 28
|
Intramuscular
|
NA
|
WISTAR Rabies PM/WI38-1503-3M strain
|
Human diploid cell vaccine
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/imovax
|
|
10114
|
RabAvert
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Novartis
|
NA
|
NA
|
All age group
|
4 doses on day 0, 3, 7 and 14
|
Intramuscular
|
NA
|
NA
|
Purified chick embryo cell
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://www.fda.gov/files/vaccines%2C%20blood%20&%20biologics/published/Package-Insert---RabAvert.pdf
|
|
10115
|
Imogam Rabies-HT
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
All age group
|
4 doses on day 0, 7 and 21 or 28
|
Intramuscular
|
NA
|
NA
|
Rabies Immunoglobin
|
Government of Canada
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://www.sanofi.ca/dam/jcr:21c480e0-afcd-4a38-bfee-fb9b7a6b21e0/imogam-rabies-pasteurized.pdf
|
|
10116
|
HyperRabTM S/D
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Talecris Biotherapeutics Bayer Biological Products
|
NA
|
NA
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
Rabies Immunoglobin
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://www.hyperrab.com/en/hcp
|
|
10117
|
Verorab
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
2015
|
France
|
NA
|
5 doses on day 0, 3, 7, 14 and 28
|
Intramuscular
|
NA
|
WISTAR Rabies PM/WI38-1503-3M strain
|
Purified vero cell rabies vaccine
|
DCGI
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://ncdc.gov.in/WriteReadData/l892s/File557.pdf
|
|
10118
|
Lyssavac N
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Zydus Candila Healthcare Limited
|
NA
|
India
|
NA
|
3 doses on day 0, 7 and 21
|
Intramuscular
|
NA
|
NA
|
Purified duck embryo cell
|
WHO
|
Berna Biotech
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.moph.go.th/sites/drug/Summary/1C_278_50_Lyssavac%20N%20Injection.pdf
|
https://www.livemint.com/Companies/XopdfNnBp4Y6189QY3PY2N/Zydus-Cadila-receives-WHO-nod-for-rabies-vaccine.html
|
|
10119
|
Rabipur
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
NA
|
All age group
|
3 doses on day 0, 7 and 21
|
Intramuscular
|
NA
|
NA
|
Purified chick embryo cell
|
DCGI
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://www.wbhealth.gov.in/uploaded_files/IDSP/Guideline_Rabies_prophylaxis_PPT_PDF.pdf
|
|
10120
|
Rabivax-S
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Ross University School of Veterinary Medicine
|
2019
|
India
|
All age group
|
3 doses on day 0, 7 and 21
|
Intramuscular
|
NA
|
NA
|
Human diploid cell vaccine
|
DCGI
|
Serum Institute of India
|
NA
|
NA
|
NA
|
NCT03741270
|
https://clinicaltrials.gov/ct2/show/NCT03741270
|
http://test.pharmabiz.com/news/serum-institute-launches-rabies-vaccine-rabivax-24382
|
|
10122
|
Speeda
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Beijing Center for Disease Control and Prevention
|
2013
|
China
|
NA
|
3 doses on day 0, 7 and 21
|
Intramuscular
|
NA
|
NA
|
NA
|
Thailand FDA
|
NA
|
NA
|
NA
|
NA
|
NCT01821911
|
https://clinicaltrials.gov/ct2/show/NCT01821911?cond=Rabies+Human&phase=23&draw=2&rank=7
|
https://www.immunize.org/askexperts/experts_rab.asp
|
|
10124
|
ENCEVAC
|
Viral encephalitis
|
Neurologic
|
West Nile virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Research Foundation for Microbial Diseases of Osaka University
|
NA
|
NA
|
NA
|
NA
|
Subcutaneous
|
NA
|
Beijing-1(P1)
|
Cell culture based
|
NA
|
NA
|
NA
|
JEBIK V (BIKEN), KD-287, JEIMMUGEN INJ (Kaketsuken)
|
24161909
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/
|
https://ifli.wisc.edu/wp-content/uploads/sites/528/2019/05/Japanese-Encephalitis.pdf
|
|
10125
|
IXIARO
|
Viral encephalitis
|
Neurologic
|
West Nile virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Valneva
|
NA
|
UK
|
2 months and above
|
2 doses 28 days apart
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Beijing-3(P3), SA14-14-2
|
Cell culture based
|
US FDA
|
NA
|
New Zealand, Europe, India, China, US, Japan
|
IC51, JESPECT, JEEV (Intercell AG) in Australia
|
24161909
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/ixiaro
|
|
10127
|
IPOL
|
Poliomyelitis
|
Neurologic
|
Poliovirus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
6 months and above
|
2-3 doses depending on volume and age
|
Intramuscular
|
NA
|
P1, P2 and P3
|
Monkey kidney cell
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/ipol-poliovirus-vaccine-inactivated-monkey-kidney-cell
|
NA
|
|
10128
|
KINRIX
|
Poliomyelitis
|
Neurologic
|
Poliovirus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
2008
|
NA
|
4 - 6 years
|
5 doses
|
Intramuscular
|
NA
|
P1, P2 and P4
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/kinrix
|
NA
|
|
10129
|
PEDIARIX
|
Poliomyelitis
|
Neurologic
|
Poliovirus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
2002
|
NA
|
6 weeks - 6 years
|
3 doses at regimen of 2, 4, and 6 months of age.
|
Intramuscular
|
NA
|
P1, P2 and P5
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/pediarix
|
NA
|
|
10130
|
Pentacel
|
Poliomyelitis
|
Neurologic
|
Poliovirus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
2008
|
NA
|
6 weeks - 4 years
|
4 doses at regimen of 2, 4, 6 and 15-18 months of age
|
Intramuscular
|
NA
|
P1, P2 and P6
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/pentacel
|
NA
|
|
10143
|
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
|
Influenza (flu)
|
Respiratory
|
Influenza A virus H5N1
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
ID Biomedical Corporation of Quebec
|
2013
|
USA
|
6 months and above
|
2 doses 21 days apart
|
Intramuscular
|
AS03
|
A/H5N1 influenza antigen
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/87479/download
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/influenza-h5n1-virus-monovalent-vaccine-adjuvanted
|
|
10144
|
AUDENZ
|
Influenza (flu)
|
Respiratory
|
Influenza A virus H5N1
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
2020
|
USA
|
6 months and above
|
2 doses 21 days apart
|
Intramuscular
|
MF59
|
Influenza virus strain A/turkey/Turkey/1/2005-NIBRG-23
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/135020/download
|
https://www.fda.gov/vaccines-blood-biologics/audenz
|
|
10145
|
Fluvirin
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
USA
|
4 years and above
|
2 doses at least 1 month apart
|
Intramuscular
|
NA
|
Influenza subtypes A and B
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/75156/download
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/fluvirin
|
|
10146
|
KCONVAC
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 1
|
Beijing Minhai Biotechnology Co. Ltd.
|
2021
|
China
|
18 years and above
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT04758273
|
https://clinicaltrials.gov/show/NCT04758273
|
https://covid-19pharmacovigilance.paho.org/sinopharmbibp
|
|
10159
|
KCONVAC
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 1
|
Shenzhen Kangtai Biological Products Co. Ltd
|
NA
|
NA
|
NA
|
1- 3 doses depending on volume and age
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Inactivated SARS-CoV-2 vaccine (Vero cell)
|
33816047
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
NA
|
|
10165
|
Koçak-19 Inaktif Covid-19 Vaccine
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 1
|
Kocak Farma
|
2021
|
Turkey
|
18 - 55 years
|
2 doses 21 days apart
|
Intramuscular
|
NA
|
SARS CoV 2 whole virus
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT04838080
|
https://clinicaltrials.gov/ct2/show/NCT04838080
|
NA
|
|
10171
|
SARS-CoV-2 VLP vaccine
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 1
|
The Scientific and Technological Research Council of Turkey
|
2021
|
Turkey
|
18 - 45 years
|
2 doses 21 days apart
|
Subcutaneous
|
Alumium hydroxide, CpG ODN
|
Inactivated SARS-CoV-2 virus
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT04866069
|
https://clinicaltrials.gov/ct2/show/study/NCT04866069
|
NA
|
|
10185
|
Turkovac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 1
|
Health Institutes of Turkey
|
2020
|
Turkey
|
18 - 55 years
|
2 doses 21 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
ERUCOV-VAC
|
NA
|
NCT04691947
|
https://clinicaltrials.gov/show/NCT04691947
|
NA
|
|
10198
|
Inactivated SARS-CoV vaccine (ISCV)
|
SARS
|
Respiratory
|
SARS-CoV
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 1
|
Sinovac Biotech Ltd.
|
NA
|
China
|
NA
|
NA
|
NA
|
CpG 1018, alum
|
SARS CoV
|
NA
|
NA
|
NA
|
NA
|
NA
|
33341119
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749790/
|
NA
|
|
10209
|
XRX-001 Inactivated yellow fever vaccine
|
Yellow fever
|
Hemorrhagic
|
Yellow fever virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 1
|
GE Healthcare
|
2016
|
USA
|
18 - 49 years
|
NA
|
NA
|
Aluminum (alum)
|
Yellow fever virus
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT00995865
|
https://clinicaltrials.gov/ct2/show/NCT00995865?recrs=abde&cond=yellow+fever&phase=0123&draw=2&rank=4
|
NA
|
|
10210
|
DENV-1 PIV
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 1
|
US Army Medical Research and Development Command
|
2015
|
USA
|
18 - 50 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
Dengue virus serotypes -1
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT01502735
|
https://clinicaltrials.gov/ct2/show/NCT01502735?recrs=abde&cond=dengue+fever&phase=0123&draw=2&rank=5
|
NA
|
|
10243
|
VLA2001 Inactivated SARS-CoV-2 vaccine (Vero cell)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 2
|
Valneva
|
2020
|
Austria
|
18 - 55 years
|
2 doses 21 days apart
|
Intramuscular
|
CpG 1018, aluminium hydroxide
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT04671017
|
https://clinicaltrials.gov/show/NCT04671017
|
NA
|
|
10256
|
KD-414
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 2
|
KM Biologics Co. Ltd.
|
2021
|
Japan
|
20 years and above
|
2 doses 27 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://jrct.niph.go.jp/en-latest-detail/jRCT2071200106
|
NA
|
|
10287
|
QazVac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 2
|
Research Institute for Biological Safety Problems
|
2020
|
Kazakhstan
|
18 years and above
|
2 doses 21 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
QazCovid-in
|
NA
|
NCT04530357
|
https://clinicaltrials.gov/show/NCT04530357
|
NA
|
|
10315
|
Omicron COVID-19 Vaccine (Vero Cell), Inactivated
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
China National Biotec Group Company Limited
|
2020
|
China
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
http://www.chictr.org.cn/showproj.aspx?proj=62581
|
https://covid-19pharmacovigilance.paho.org/sinopharmbibp
|
|
10316
|
Inactivated SARS-CoV-2 vaccine (Vero cell)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Laboratorio Elea Phoenix S.A.
|
2020
|
Argentina
|
18 - 85 years
|
2 doses 21 days apart
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
SARS-CoV-2 HB02 strain
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT04560881
|
https://clinicaltrials.gov/show/NCT04560881
|
NA
|
|
10317
|
Inactivated SARS-CoV-2 vaccine (Vero cell)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Health Institutes of Turkey
|
2020
|
Turkey
|
18 - 59 years
|
2 doses 14 days apart
|
Intramuscular
|
NA
|
SARS-CoV-2 virus antigenic protein
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT04582344
|
https://clinicaltrials.gov/show/NCT04582344
|
NA
|
|
10321
|
WIBP-CorV
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Sinopharm, Wuhan Institute of Biological Products
|
2021
|
China
|
18 years and above
|
2 doses 21 days apart
|
Intramuscular
|
NA
|
SARS-CoV-2 whole virus
|
NA
|
NA
|
G42 Healthcare company, Abu Dhabi Health Services Company, Wuhan Institute of Biological Products Co. Ltd, Beijing Institute of Biological Products Co Ltd.
|
China, UAE
|
Zhongkangkewei
|
33816047
|
NCT04510207
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
https://clinicaltrials.gov/ct2/show/NCT04510207
|
|
10327
|
Covaxin
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Bharat Biotech International Limited
|
NA
|
India
|
NA
|
2 doses 14 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
BBV152
|
33816047
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
NA
|
|
10332
|
QazVac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Research Institute for Biological Safety Problems
|
2021
|
Kazakhstan
|
18 years and above
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
QazCovid-in
|
33816047
|
NCT04691908
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
NA
|
|
10342
|
WIBP-CorV
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Wuhan Institute of Biological Products
|
NA
|
NA
|
18 - 59 years
|
Single dose
|
Intramuscular
|
NA
|
Inactivated SARS-CoV-2 virus
|
NA
|
NA
|
NA
|
NA
|
NVX-CoV2373
|
33402220
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/
|
NA
|
|
10347
|
COVIran Barekat
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Shifa Pharmed Industrial Co.
|
2021
|
Iran
|
18 - 75 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
BIV1-CovIran, COVIran Barkat
|
NA
|
NA
|
http://en.irct.ir/trial/54881
|
https://en.irct.ir/trial/52701
|
|
10351
|
QazVac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Research Institute for Biological Safety Problems
|
2020
|
Kazakhstan
|
18 years and above
|
2 doses 21 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
QazCovid-in
|
NA
|
NCT04691908
|
https://clinicaltrials.gov/show/NCT04691908
|
NA
|
|
10353
|
COVIVAC
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Instituto Butantan
|
2020
|
Brazil
|
18 years and above
|
2 doses 2 weeks apart
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
ADAPTCOV, NDV-HXP-S vaccine, , HXP-GPOVac, Patria, ButanVac
|
NA
|
NCT04456595
|
https://clinicaltrials.gov/show/NCT04456595
|
NA
|
|
10355
|
CoviVac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Chumakov Centre at the Russian Academy of Sciences
|
2021
|
Russia
|
18 - 60 years
|
2 doses 14 days apart
|
Intramuscular
|
NA
|
Inactivated SARS-CoV-2 virus
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.precisionvaccinations.com/vaccines/covivac-russia-covid-19-vaccine
|
NA
|
|
10356
|
V70P5
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Novartis
|
2015
|
USA
|
6 months - 71 months
|
2 doses
|
Intramuscular
|
NA
|
Inactivated Influenza virus
|
NA
|
NA
|
NA
|
NA
|
NBP607
|
NA
|
NCT00644059
|
https://clinicaltrials.gov/ct2/show/NCT00644059?recrs=ade&cond=Influenza%2C+Human&phase=23&draw=2&rank=14
|
NA
|
|
10357
|
NBP607-QIV
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
SK Chemicals Co. Ltd.
|
2015
|
South Korea
|
6 months - 18 years
|
1- 2 doses depending on volume and age
|
Intramuscular
|
NA
|
Inactivated Influenza virus
|
Cell culture based
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT02914275
|
https://clinicaltrials.gov/ct2/show/NCT02914275?recrs=ade&cond=Influenza%2C+Human&phase=23&draw=2&rank=18
|
NA
|
|
10358
|
Seqirus QIV
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Seqirus
|
2019
|
USA
|
6 months - 59 months
|
1- 2 doses depending on volume and age
|
Intramuscular
|
NA
|
Four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT02914275
|
https://www.clinicaltrials.gov/ct2/show/NCT02914275
|
NA
|
|
10366
|
EPAXAL
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Crucell, Berna Biotech
|
NA
|
Berne, Switzerland
|
NA
|
P: 24 U; Adults: 24 U
|
Intramuscular
|
NA
|
RG-SB
|
NA
|
NA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
NA
|
|
10367
|
Aimugen
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 3
|
Chemo-Sero-Therapeutic Research Institute
|
NA
|
Japan
|
NA
|
P: 0.5 µg; Adults: 0.5 µg
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
KRM003
|
NA
|
NA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
NA
|
|
10368
|
Hepatyrix
|
Hepatitis A, Typhoid
|
Hepatitic
|
Hepatitis A virus, Salmonella typhi
|
double stranded DNA
|
Inactivated
|
Phase 3
|
Sanofi Pasteur
|
2015
|
Belgium
|
15 years and above
|
Single dose
|
Intramuscular
|
NA
|
Hepatitis A viral protein along with Vi polysaccharide antigen (a part of the Salmonella typhi (Ty2 strain) bacterium
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.hpra.ie/img/uploaded/vaccines/PIL_PA1077099001.pdf
|
NA
|
|
10379
|
Bulgarian vaccine
|
Crimean-Congo haemorrhagic fever
|
Hemorrhagic
|
Nairovirus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Preclinical
|
NA
|
1974
|
Union of Soviet Socialist Republics
|
16 years and above
|
NA
|
Subcutaneous
|
Aluminum (aluminium hydroxide)
|
NA
|
Prepared from brain tissue of CCHFV infected newborn mice
|
NA
|
NA
|
NA
|
Zabdeno, Mvabea
|
32461819
|
NA
|
https://www.liebertpub.com/doi/10.1089/biores.2019.0057
|
https://www.ema.europa.eu/en/documents/product-information/zabdeno-epar-product-information_en.pdf
|
|
10409
|
UV-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
CHIKV proteins
|
Inactivated by UV-irradiation
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10410
|
BEI-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
CHIKV proteins
|
Inactivated by binary ethyleneimine
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10411
|
Formalin-inactivated CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
CHIKV proteins
|
Inactivated by formalin
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|
|
10412
|
Tween/Ether-CHIKV
|
Chikungunya fever
|
Exanthous
|
Chikungunya virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Preclinical
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
CHIKV proteins
|
Inactivated by Tween 80 and ether
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://link.springer.com/chapter/10.1007/82_2019_175
|
NA
|